Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:32am, Friday, 03'rd Feb 2023
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
If You Want Tons of Passive Income in the Future , Buy These 2 Stocks
10:07am, Friday, 03'rd Feb 2023
Good cash flows come to those who pick intelligently and wait.
Top Fund Manager Found A Way To Make Money While Others Lose
07:00am, Friday, 03'rd Feb 2023
Making money in an up market is easy. But showering investors with gains when stocks fall is far more challenging for the best mutual funds.
Compounders And Dividends: January 2023 Portfolio Update
05:22am, Friday, 03'rd Feb 2023 Seeking Alpha
My January 2023 income is multiples higher than my January 2022 dividend income. Read more to see an update on my portfolio.
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
03:01pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
02:53pm, Thursday, 02'nd Feb 2023 The Motley Fool
These stocks are growing steadily and have a solid history of enriching shareholders.
3 Ultra-Profitable Businesses to Invest in for the Long Haul
02:00pm, Thursday, 02'nd Feb 2023 The Motley Fool
These companies all have profit margins of at least 20%.
Merck (MRK) Beats Q4 Earnings and Revenue Estimates
12:55pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
11:20am, Thursday, 02'nd Feb 2023 Zacks Investment Research
Smart Beta ETF report for NOBL
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints
03:31pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February
10:55am, Wednesday, 01'st Feb 2023 The Motley Fool
These stocks aren't in Berkshire Hathaway's SEC filings, but Buffett owns them.
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February
05:55am, Wednesday, 01'st Feb 2023
These stocks aren't in Berkshire Hathaway's SEC filings, but Buffett owns them.
10 Biggest Companies Reporting Earnings in the Second Week of Feb 2023
10:55pm, Tuesday, 31'st Jan 2023
The fourth quarter 2022 earnings season continues to be subpar for the S&P 500.
Amgen's Q4 tops views, but 2023 guidance falls on lower end of expectations
09:44pm, Tuesday, 31'st Jan 2023 MarketWatch
Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations.
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
01:15pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
